Background Renal involvement is uncommon in diffuse large B-cell lymphoma. Recent data
suggest that it is an independent risk factor for central nervous system relapse. We reviewed …

Background: Extranodal non-Hodgkin lymphoma (NHL) accounts for much of the increases
in NHL incidence in the past three decades in the United States, but its descriptive …

The addition of rituximab (R) to standard CHOP (cyclophosphamide, doxorubicin, vincristine,
and prednisone) chemotherapy has altered the significance of previously recognized …

Using a DNA microarray approach to screen for gene copy number changes in 20 colorectal
(CR) carcinoma samples and filtering for high‐level DNA copy number changes, we …

Background: Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered
in several solid and haematological tumours. ALK gene copy number changes and …

Central nervous system (CNS) relapse is a challenging complication in patients with diffuse
large B-cell lymphoma (DLBCL). Thus, identification of the high-risk population, in whom …

In order to evaluate prognostic value of CD99 expression in patients with diffuse large B-cell
lymphoma (DLBCL) who underwent treatment with rituximab-CHOP immunochemotherapy …

B-cell activating factor belonging to the tumor necrosis factor family (BAFF) is a fundamental
survival factor for B-cells, and BAFF functionality is indispensable for B-cell maturation. BAFF …

Objectives: Estrogen receptor beta (ERβ)-selective agonists inhibited B cell lymphoma
growth in animal models. However, a recent study found that higher ERβ expression in …

Abstract Background About 20%‐30% of diffuse large B‐cell lymphoma (DLBCL) patients
experience early disease progression despite R‐CHOP chemotherapy treatment. Revised …